What Apollo Therapeutics does

Apollo Therapeutics is a portfolio biopharmaceutical company founded in 2015 and headquartered in Cambridge, United Kingdom, that translates breakthroughs in biology and basic medical research into innovative new medicines. The company operates a scalable R&D platform built on partnerships with six of the UK's leading universities and research institutes — including the University of Cambridge, Imperial College London, King's College London, and UCL — providing continuous access to upstream scientific discovery. Its pipeline spans oncology, immunology, and rare diseases and currently comprises over 20 active therapeutic programs, of which five to six are in clinical-stage development; the portfolio is deliberately structured to provide uncorrelated risk across multiple programs.

The company augments its university-derived pipeline through in-licensing and acquisition of clinical-stage programs where its internal discovery work creates unique synergies. Its core "product" is the therapeutic pipeline itself rather than any single molecule; Apollo is pre-revenue with no approved or commercialized medicines, and pricing is therefore not yet applicable. Future revenue is expected to be generated through licensing deals and royalties with major pharmaceutical partners or, eventually, through direct commercialization of approved therapies.

Apollo is backed by specialist healthcare investors led by Patient Square Capital, with additional participation from Rock Springs Capital, M&G plc, US public pension plans, Reimagined Ventures, UCL Technology Fund, and IP Group. Total disclosed funding exceeds $400 million, anchored by a $145 million Series B in June 2021 and a $260 million Series C closed in two tranches in September and December 2023. The company maintains UK R&D operations in Cambridge and Oxford alongside US offices in Boston and Chicago, and has appointed Timothy P. Walbert — former Chairman, President and CEO of Horizon Therapeutics through its approximately $28.3 billion acquisition by Amgen in 2023 — as Chairman to support late-stage clinical execution and eventual commercialization.

Name

Apollo Therapeutics

Legal name

Apollo Therapeutics Ltd.

Website

https://apollotherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Apollo Therapeutics is a UK-based portfolio biopharmaceutical company that translates academic research breakthroughs into new medicines across oncology, immunology, and rare diseases. It operates a diversified pipeline of over 20 programs built on partnerships with six leading UK universities.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Biopharmaceutical development
• Drug discovery platform
• Clinical-stage therapeutics
• Oncology immunology pipeline
• Rare disease medicines

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing a diversified portfolio of therapeutic programs in oncology, immunology, and rare diseases. Revenue will be generated through eventual commercialization of developed medicines, either directly or through partnerships with major pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Apollo Therapeutics is a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. It operates a scalable R&D platform with access to science from six of the world's leading universities and research institutes, advancing over 20 active therapeutic programs (six in clinical development) across oncology, immunology, and rare diseases. The company supplements internal R&D with in-licensing and acquisition of clinical-stage programs where it has unique insights and synergies, and ultimately intends to commercialize medicines through partnerships with major pharmaceutical companies or directly.

Product overview

Apollo Therapeutics operates as a portfolio biopharmaceutical company that translates breakthroughs in biology and basic medical research into innovative new medicines. The company maintains a scalable R&D platform enabled by unprecedented access to research from six of the world's leading universities and research institutes. Its core product is the therapeutic programs pipeline comprising over 20 active programs, with six in clinical development. The portfolio model provides diversified novel therapeutics with uncorrelated risk, augmented by in-licensing and acquisition of clinical-stage programs where unique insights and synergies exist.

Differentiator

Problem solved

Functional benefit

Products and services

• Therapeutic Programs Pipeline

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• University of CambridgecoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.
• Imperial College LondoncoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development programs, part of the six universities providing breakthrough science access.
• King's College LondoncoreStrategic or Co-development Partner · 1 September 2023Research institution partner for drug discovery and development activities, part of university research collaboration network.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• PureTech Health: PureTech Health is a clinical-stage biotherapeutics company that translates academic and scientific research into medicines through a portfolio of programs — closely mirroring Apollo's model of sourcing programs from leading research institutions and advancing them via a centralized R&D platform.
• Roivant Sciences: Roivant Sciences operates a portfolio model that in-licenses and develops therapeutic programs across multiple therapeutic areas, leveraging a hub-and-spoke structure to advance diverse assets — highly analogous to Apollo's diversified portfolio approach.
• BridgeBio Pharma: BridgeBio Pharma is a portfolio biopharma building multiple drugs for genetic diseases and rare conditions across separate subsidiaries. Apollo shares the portfolio strategy and rare disease therapeutic focus, though Apollo's pipeline spans oncology and immunology more broadly.
• Centessa Pharmaceuticals: Centessa Pharmaceuticals is a clinical-stage pharmaceutical company with a portfolio of multiple asset-centric programs operated under a unified R&D infrastructure — the same capital allocation and shared platform philosophy Apollo applies to its 20+ programs.
• Nimbus Therapeutics: Nimbus Therapeutics is a clinical-stage biotech that designs and develops a portfolio of small molecule therapeutics across multiple disease areas using structure-based drug design — sharing Apollo's strategy of advancing multiple therapeutic programs in parallel with deep R&D capabilities.

Emerging players

• Medicxi: Medicxi is a life sciences-focused investment firm that develops and owns therapeutic programs originating from European academic research, sharing Apollo's translational academic-to-industry pipeline approach and European biotech origins.
• Isomorphic Labs: Isomorphic Labs is an Alphabet-backed drug discovery company applying AI to accelerate therapeutic development, with a portfolio approach to multiple programs. It overlaps with Apollo's translational model of building a diversified pipeline, but via AI-driven rather than academic-sourced discovery.

Broad incumbents

• Recursion Pharmaceuticals: Recursion is a clinical-stage biotech using an AI-enabled platform to advance a portfolio of discovered and in-licensed therapeutic programs. While more technology-centric, it competes in similar early-stage drug discovery with a portfolio-style pipeline philosophy.
• Exscientia: Exscientia is an AI-driven pharmatech company that partners with pharma to discover and develop small molecule therapeutics across multiple programs — adjacent to Apollo in building diversified pipelines, though enabled by computational rather than academic-sourced discovery.
• Schrödinger: Schrödinger operates a computational drug discovery platform and advances an internal pipeline of wholly-owned and partnered programs. Comparable to Apollo as a portfolio biopharma with differentiated discovery capabilities, though based on physics-based simulation rather than university partnerships.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/apollo-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apollo Therapeutics